Lario Therapeutics
Develops disease-modifying precision medicines for severe epileptic disorders and Parkinson's disease, starting
Highlights
- Young companyFounded 2021
- New on EvolcAdded 2026-10-30
About Lario Therapeutics
Lario Therapeutics is a biopharmaceutical company developing first-in-class precision medicines as disease-modifying treatments for severe neurological disorders, including epileptic conditions and Parkinson's disease. Its pipeline starts from genetically validated targets, and its programmes include CaV2.3 calcium channel inhibitors.
The company targets developmental and epileptic encephalopathies and neurodegenerative disorders. Its research is funded by seed investment from Epidarex Capital and Axxam, which transferred to Golgi Neurosciences, and by grants, including a $6M grant from The Michael J. Fox Foundation for preclinical work on CaV2.3 inhibitors in Parkinson's research.
Lario was founded in 2021 as a spin-out from Epidarex Exeed, the therapeutic discovery engine of Epidarex Capital. It is headquartered in Edinburgh, UK. In February 2026 it was awarded $2.4m by The Michael J. Fox Foundation and Wellcome to expand its calcium channel platform into Parkinson's disease and PTSD.
Product: Preclinical precision medicines, including CaV2.3 calcium channel inhibitors, for epileptic conditions and Parkinson's disease.
Jobs at Lario Therapeutics
Leadership
- Daniel Gill · Co-founder, Head of Operations & Project ManagementSource: company website
- Henning Steinhagen · Co-founder & AdvisorSource: company website
- Richard Brooks · Financial DirectorSource: company website
More biotech & pharma companies
Levicept
Develops a non-opioid biologic treatment for osteoarthritis pain for patients with painful joint diseaseNew on EvolcLGC Group
Reference materials, diagnostic quality controls and analytical standards for labs and life-science companiesNew on EvolcLibero Pharma
Develops transdermal naltrexone patches for patients with addiction, fibromyalgia and Crohn’s diseaseNew on EvolcLightcast Discovery
Single-cell functional screening platform for antibody and drug discovery teams in biotech and pharma researchNew on EvolcLiminal Biosciences
Develops small-molecule therapeutics for metabolic, inflammatory and fibrotic diseases through GPCR pathwaysNew on EvolcLindus Health
Clinical development of in-licensed drug assets for biotech and pharma partners, run on an AI clinical trial platformNew on EvolcRemote-friendly
Website technologies
Older, unverified list. Detection dates and supporting evidence are not yet available.
- Cloudflare
- Fastly
- React
- Sentry
- Wix